Wells Fargo raised the firm’s price target on Editas Medicine (EDIT) to $4 from $3 and keeps an Equal Weight rating on the shares. The firm thinks the LDLR upregulation mechanism leveraged by EDIT-401 is intriguing, with the promise of a potent new approach to lower LDL-C. Wells does think initial derisking on the safety of this new approach would be helpful and awaits updates on IND in 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT:
- Editas Medicine Advances EDIT-401 for LDL Reduction
- Editas Medicine nominates EDIT-401 as lead in vivo development candidate
- Editas Medicine: Strategic Position Balances Cautious Development and Financial Stability
- Editas Medicine price target raised to $5 from $3 at H.C. Wainwright
- Editas Medicine Inc. Faces Significant Business Risks: Key Factors for Investors to Watch